

# Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis

Mengyang Di,<sup>1,2</sup> Jessica B. Long,<sup>2</sup> Shalin K. Kothari,<sup>1</sup> Tarsheen Sethi,<sup>1</sup> Amer M. Zeidan,<sup>1,2</sup> Nikolai A. Podoltsev,<sup>1,2</sup> Rory M. Shallis,<sup>1,2</sup> Rong Wang,<sup>2,3</sup> Xiaomei Ma<sup>2,3</sup> and Scott F. Huntington<sup>1,2</sup>

<sup>1</sup>Section of Hematology, Department of Internal Medicine, Yale School of Medicine; <sup>2</sup>Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center and <sup>3</sup>Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

Correspondence:

M. DI - mengyang.di@yale.edu

<https://doi.org/10.3324/haematol.2022.282252>


**Supplementary Table S1. Codes used to identify systemic therapy and autologous stem cell transplant for mantle cell lymphoma**

	<b>HCPCS</b>	<b>ICD-9 Diagnosis</b>	<b>ICD-10 Diagnosis</b>	<b>ICD-9 Procedure</b>	<b>ICD-10 Procedure</b>	<b>DRG</b>
<b>Chemotherapy</b>	96400-96549, Q0083-Q0085, G0355-G0362, J9000-J9999, C8953, C8954, C8955, J0640, J8510, J8520, J8521, J8530, J8560, J8565, J8600, J8610, J8700, J8999, C1178, C8953, C8954, C8955, C9120, C9253, C9414, C9420, C9421, C9425, C9427, C9431, C9432, C9433	V581	Z5111, Z5112	9925	3E0*, XW0*	840, 841, 842
<b>Stem cell/bone marrow transplant</b>	38205, 38206, 38230, 38232, 38240, 38241, 38242, 38243, S2150			410	30230AZ, 30230G0, 30230G3, 30230G4, 30230X0, 30230X4, 30230Y0, 30230Y3, 30230Y4, 30233AZ, 30233G0, 30233G3, 30233G4, 30233X0, 30233X4, 30233Y0, 30233Y3, 30233Y4, 30240AZ, 30240G0, 30240G3, 30240G4, 30240X0, 30240X4, 30240Y0, 30240Y3, 30240Y4, 30243AZ, 30243G0, 30243G3, 30243G4, 30243X0, 30243X4, 30243Y0, 30243Y3, 30243Y4	014, 016, 017
<b>Drug</b>						
	<b>HCPCS (from NCH and OUTSAF)</b>					
Rituximab	J9310, J9311, J9312					
Cyclophosphamide	J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J9097					
Doxorubicin	J9000, J9001, C9415, J9002, Q2048, Q2049, Q2050					
Vincristine	J9370, J9375, J9380, J9371					
Cytarabine	C9422, J9098, J9100, J9110, J9153, C9024					
Bendamustine	J9033, J9034, C9423, J9036, C9042					
Gemcitabine	J9201					
Carboplatin	J9045					
Cisplatin	J9060, J9062, C9418					
Oxaliplatin	J9253					
Methotrexate	J8610, J9250, J9260					
Bortezomib	J9041, J9044					


We used the following part D generic names to identify oral agents for mantle cell lymphoma: venetoclax, ibrutinib, acalabrutinib, zanubrutinib, lenalidomide, prednisone.

**Supplementary Figure S1. Probabilities of receiving rituximab maintenance between the maintenance and non-maintenance groups. A. Before propensity score matching, B. After propensity score matching.**

**A.**



**B.**



Histograms were converted to density plots in compliance with NCI's policy in reporting.

**Supplementary Table S2. Results of sensitivity analysis on real-world effectiveness of rituximab maintenance**

<b>Sensitivity analysis</b>	<b>Outcome</b>	<b>Effect measure</b>	<b>Maintenance vs. No maintenance</b>
<b>Treatment gap=120 days (RM group)</b>	All-cause mortality	HR (95% CI)	0.49 (0.31, 0.77)
	Mortality or second-line therapy	HR (95% CI)	0.49 (0.34, 0.71)
	Receipt of second-line therapy	sHR (95% CI)	0.52 (0.34, 0.79)
<b>Treatment gap=150 days (Non-RM group)</b>	All-cause mortality	HR (95% CI)	0.51 (0.34, 0.76)
	Mortality or second-line therapy	HR (95% CI)	0.47 (0.34, 0.66)
	Receipt of second-line therapy	sHR (95% CI)	0.43 (0.30, 0.62)
<b>Treatment gap=180 days (Non-RM group)</b>	All-cause mortality	HR (95% CI)	0.39 (0.25, 0.61)
	Mortality or second-line therapy	HR (95% CI)	0.43 (0.31, 0.61)
	Receipt of second-line therapy	sHR (95% CI)	0.44 (0.30, 0.65)
<b>Treatment gap=210 days (Non-RM group)</b>	All-cause mortality	HR (95% CI)	0.52 (0.34, 0.79)
	Mortality or second-line therapy	HR (95% CI)	0.58 (0.42, 0.82)
	Receipt of second-line therapy	sHR (95% CI)	0.66 (0.45, 0.96)
<b>Start of follow-up: End of first-line therapy</b>	All-cause mortality	HR (95% CI)	0.56 (0.37, 0.85)
	Mortality or second-line therapy	HR (95% CI)	0.50 (0.36, 0.71)
	Receipt of second-line therapy	sHR (95% CI)	0.51 (0.35, 0.74)

HR= Hazard ratio, sHR= Subdistribution hazard ratio, CI= Confidence interval, RM= Rituximab maintenance